Erickson BK, Conner MG, Landen CN Jr (2013) The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 209:409–414

Article  PubMed  PubMed Central  Google Scholar 

Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61:183–203

Article  PubMed  PubMed Central  Google Scholar 

Zon A, Bednarek I (2023) Cisplatin in ovarian Cancer treatment-known limitations in Therapy Force New solutions. Int J Mol Sci 24:7585

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ortiz M, Wabel E, Mitchell K, Horibata S (2022) Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist 5:304–316

CAS  PubMed  PubMed Central  Google Scholar 

Ghosh S (2019) Cisplatin: the first metal based anticancer drug. Bioorg Chem 88:102925

Article  CAS  PubMed  Google Scholar 

Oun R, Rowan E (2017) Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? Eur J Pharmacol 811:125–128

Article  CAS  PubMed  Google Scholar 

Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263–302

Article  CAS  PubMed  Google Scholar 

Xing JJ, Hou JG, Liu Y et al (2019) Supplementation of Saponins from leaves of Panax quinquefolius mitigates cisplatin-evoked cardiotoxicity via inhibiting oxidative stress-Associated inflammation and apoptosis in mice. Antioxid (Basel) 8:347

Article  CAS  Google Scholar 

Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA (2006) Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res 53:278–286

Article  CAS  PubMed  Google Scholar 

Palazzo A, Ciccarese C, Iacovelli R et al (2023) Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. ESMO Open 8:101154

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hockings H, Miller RE (2023) The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol 15:17588359231173183

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateo J, Lord CJ, Serra V et al (2019) A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 30:1437–1447

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henning RJ, Bourgeois M, Harbison RD (2018) Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors: mechanisms of Action and Role in Cardiovascular disorders. Cardiovasc Toxicol 18:493–506

Article  CAS  PubMed  Google Scholar 

Fiorillo C, Ponziani V, Giannini L et al (2006) Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts. Cell Mol Life Sci 63:3061–3071

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gilad E, Zingarelli B, Salzman AL, Szabo C (1997) Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 29:2585–2597

Article  CAS  PubMed  Google Scholar 

Morrow DA, Brickman CM, Murphy SA et al (2009) A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis 27:359–364

Article  CAS  PubMed  Google Scholar 

Pacher P, Liaudet L, Bai P et al (2002) Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300:862–867

Article  CAS  PubMed  Google Scholar 

Pacher P, Liaudet L, Mabley JG, Cziraki A, Hasko G, Szabo C (2006) Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 17:369–375

CAS  PubMed  Google Scholar 

Szenczi O, Kemecsei P, Holthuijsen MF et al (2005) Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 69:725–732

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for Health Research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32:718–728

Article  PubMed  PubMed Central  Google Scholar 

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

Article  CAS  PubMed  Google Scholar 

Morelli MB, Bongiovanni C, Da Pra S et al (2022) Cardiotoxicity of Anticancer drugs: molecular mechanisms and strategies for Cardioprotection. Front Cardiovasc Med 9:847012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988

Article  CAS  PubMed  Google Scholar 

Yao XI, Wang X, Speicher PJ et al (2017) Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst 109:1–9

Article  Google Scholar 

Dieras V, Han HS, Kaufman B et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282

Article  CAS  PubMed  Google Scholar 

Bang YJ, Xu RH, Chin K et al (2017) Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1637–1651

Article  CAS  PubMed  Google Scholar